Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer

[1]  A. Sasse,et al.  Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis , 2011, BMC Cancer.

[2]  D. Moher,et al.  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[3]  P. Royston,et al.  Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial , 2010 .

[4]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[5]  R. Figlin,et al.  An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial , 2008, The Lancet.

[6]  J. Lam,et al.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. , 2005, The Journal of urology.

[7]  J. Lam,et al.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. , 2005, The Journal of urology.

[8]  Gareth Griffiths,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. , 1999, Lancet.

[9]  P. Fayers,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial , 1999 .

[10]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[11]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[12]  K. Haustermans,et al.  Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. , 1997, The Journal of urology.

[13]  N. Black.  CONSORT , 1996, The Lancet.

[14]  S. Al-Askari,et al.  Renal cell carcinoma: survival and prognostic factors. , 1986, Urology.

[15]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[16]  C. Wood.  Adjuvant approaches to renal cell carcinoma. , 2008, Clinical advances in hematology & oncology : H&O.

[17]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[18]  E. Lopez Hänninen,et al.  Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. , 1993, European journal of cancer.